Generated July 7, 2026 at 8:32 PM ET
· Covers July 7 trading day
· 10 of 163 ready 8-Ks selected
· AI-assisted overview
The day's most material filings included Vera Therapeutics' FDA accelerated approval for TRUTAKNA, Getty Images' termination of its Shutterstock merger, and Brag House's reverse merger with House of Doge. CareDx closed a $171M sale and a $162M acquisition, while Compass Pathways reported positive Phase 3 data for COMP360. Wheeler REIT issued common shares and adjusted a note conversion price, and leadership changes were announced at ARS Pharmaceuticals and Hughes Satellite.
SPRY
ARS Pharmaceuticals, Inc.
leadership
negative
materiality 0.70
July 7, 2026, 4:38 PM ET
ARS Pharmaceuticals appoints Donn Casale as CEO, replacing Richard Lowenthal terminated without cause
- Donn Casale, previously President, appointed CEO effective July 7, 2026.
- Richard Lowenthal terminated without cause on July 6, 2026.
- Casale also appointed to Board as Class III director until 2029 annual meeting.
GETY
Getty Images Holdings, Inc.
M&A
negative
materiality 0.85
July 7, 2026, 6:05 AM ET
Getty Images terminates merger with Shutterstock; will redeem senior secured notes
- Board terminated Merger Agreement on July 7, 2026, after CMA clearance condition not met.
- Getty Images will redeem its 10.500% senior secured notes due 2030 following termination.
- Previously, on June 30, 2026, Board resolved not to proceed with CMA-required sale of Shutterstock's editorial business.
TBH
Brag House Holdings, Inc.
M&A
positive
materiality 0.85
July 7, 2026, 5:20 PM ET
House of Doge completes reverse merger with Brag House, begins trading on Nasdaq as HODO
- Merger closed June 30, 2026; combined company renamed House of Doge Inc., begins trading on Nasdaq under ticker HODO on July 1, 2026.
- Former HOD stockholders received ~64M common shares and ~2.05 Class C preferred shares (each convertible into 5M common); post-merger ~75.9M shares outstanding.
- Former HOD owners hold ~90.66% of common stock and 83.32% fully diluted; new board of 6 directors and CEO Marco Margiotta, CFO Charles Park appointed.
M&A
positive
materiality 0.85
July 7, 2026, 5:12 PM ET
CareDx closes $171M sale of Lab Products to Eurobio, acquires Naveris for $162M+
- Sale of Lab Products business to Eurobio closed June 30 for $171.2M cash, sharpening focus on U.S. testing services.
- Acquisition of Naveris closed July 1 for $161.8M cash plus up to $100M earnout based on 2026-2027 revenue milestones.
- Naveris' NavDx test is the only Medicare-covered MRD test for HPV+ head/neck and anal cancers; 130K+ tests reported.
VERA
Vera Therapeutics, Inc.
regulatory
positive
materiality 0.90
July 7, 2026, 12:45 PM ET
FDA grants accelerated approval for Vera's TRUTAKNA (atacicept) in IgA nephropathy
- FDA granted accelerated approval for TRUTAKNA (atacicept-vymj) to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression.
- Approval announced on July 7, 2026; this is a significant regulatory milestone for Vera Therapeutics.
- The accelerated approval is based on reduction of proteinuria as a surrogate endpoint.
regulatory
positive
materiality 0.75
July 7, 2026, 8:05 AM ET
Aptera receives EPA Certificate of Conformity for 2026 Launch Edition vehicle
- EPA Certificate of Conformity issued June 18, 2026 for 2026 Aptera Launch Edition.
- CoC confirms compliance with federal emissions requirements under the Clean Air Act.
- Remaining federal requirement: compliance with FMVSS using low-volume validation assembly line.
PSTL
Postal Realty Trust, Inc.
debt
positive
materiality 0.65
July 7, 2026, 5:13 PM ET
Postal Realty recasts credit facilities to $615M with 30 bps pricing improvement
- New $275M revolver (maturing Nov 2030) and $340M term loans (2028/2029/2031) total $615M.
- Pricing improved 30 bps: revolver SOFR+115-155 bps, term loans SOFR+110-150 bps.
- Accordion feature increased to $335M ($175M revolver + $160M term loans).
WHLR
Wheeler Real Estate Investment Trust, Inc.
other material
negative
materiality 0.85
July 7, 2026, 8:21 AM ET
Wheeler REIT issues ~2.1M common shares for preferred stock; note conversion price cut to $0.67
- Issued 2,119,707 common shares in exchange for 173,383 Series B and 13,217 Series D preferred shares in June/July 2026.
- Conversion price of 7% subordinated convertible notes due 2031 adjusted to ~$0.67/share, a 45% discount to $1.22.
- July 2026 Series D redemptions: 8,200 shares redeemed at ~$40.97/share, settled with 275,883 common shares.
CMPS
COMPASS Pathways plc
other material
positive
materiality 0.85
July 7, 2026, 6:33 AM ET
Compass Pathways reports positive 26-week Phase 3 COMP006 data for COMP360 in TRD; NDA on track for Q4 2026
- 39% of 25 mg arm achieved ≥25% MADRS reduction at Week 6, maintained through Week 26.
- Retreatment in Part B enhanced benefit: nearly 30% of responders at Week 6 later achieved remission.
- Safety profile generally well-tolerated; SAEs similar across arms (6.3% vs 5.7%).
—
Hughes Satellite Systems Corp
leadership
negative
materiality 0.70
July 7, 2026, 9:01 AM ET
CEO Hamid Akhavan resigns; Charles Ergen takes over Hughes; EchoStar Capital folded
- Hamid Akhavan resigned as CEO of EchoStar Capital, President/CEO of Hughes, and board member, effective July 6, 2026.
- Charles W. Ergen assumes role as Principal Executive Officer of Hughes.
- EchoStar Capital will be folded into Corporate Development led by EVP Thomas A. Cullen.